Pfizer Inc. (NYSE: PFE) last week reported the outcomes of a Phase III trial for its respiratory syncytial virus (RSV) bivalent vaccine, Abrysvo, in adults aged 60 and above following the second RSV season. The vaccine’s efficacy against RSV-associated lower respiratory tract disease (LRTD) experienced a decline from 88.9% in the first season to 77.8% in the second. Pfizer views this variance as indicative of the vaccine’s durable efficacy, with an overall efficacy of 81.5% across both seasons and consistency across different RSV strains.
Efficacy against RSV-associated mild LRTD also showed a similar trend, decreasing from 65.1% after the first season to 55.7% after the second.
Pfizer intends to submit these data to global regulatory authorities for further consideration. Abrysvo has already received approval for various target groups in countries including Argentina, Canada, Japan, Macau, the UK, and the US.- Flcube.com
